Management of hypertension with fixed dose combinations of candesartan cilexetil and hydrochlorothiazide: patient perspectives and clinical utility (Q33571219)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Management of hypertension with fixed dose combinations of candesartan cilexetil and hydrochlorothiazide: patient perspectives and clinical utility	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

9 references

13 March 2019

17 June 2019

17 September 2019

2 October 2019

7 November 2019

2 September 2020

26 October 2020

24 November 2020

4 December 2020

Management of hypertension with fixed dose combinations of candesartan cilexetil and hydrochlorothiazide: patient perspectives and clinical utility (English)

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

arterial hypertension

7 references

13 March 2019

17 June 2019

17 September 2019

2 October 2019

7 November 2019

2 September 2020

26 October 2020

heterocyclic compound

1 reference

17 September 2019

mechanism of action

1 reference

2 October 2019

1 reference

7 November 2019

1 reference

based on heuristic

inferred from title

1 reference

2 September 2020

biphenyl compound

1 reference

26 October 2020

1 reference

24 November 2020

antihypertensive drug

1 reference

4 December 2020

hydrochlorothiazide

1 reference

based on heuristic

inferred from title

author name string

Thomas Mengden

1

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

Sakir Uen

2

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

Peter Bramlage

3

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

language of work or name

0 references

publication date

29 December 2009

10 references

Europe PubMed Central

PubMed publication ID

28 July 2017

13 March 2019

17 June 2019

17 September 2019

2 October 2019

7 November 2019

2 September 2020

26 October 2020

24 November 2020

4 December 2020

Vascular Health and Risk Management

10 references

Europe PubMed Central

PubMed publication ID

28 July 2017

13 March 2019

17 June 2019

17 September 2019

2 October 2019

7 November 2019

2 September 2020

26 October 2020

24 November 2020

4 December 2020

5

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

1043-1058

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

copyright license

Creative Commons Attribution-NonCommercial 3.0 Unported

1 November 2009

1 reference

April 2022 Public Data File from Crossref

copyright status

0 references

Fixed-dose combinations of renin-angiotensin blocking agents with calcium channel blockers or hydrochlorothiazide in the treatment of hypertension.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2801628

21 June 2018

Blood pressure reduction, persistence and costs in the evaluation of antihypertensive drug treatment--a review.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2801628

21 June 2018

Supramaximal dose of candesartan in proteinuric renal disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2801628

21 June 2018

ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2801628

21 June 2018

2007 Guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2801628

21 June 2018

Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2801628

21 June 2018

Candesartan cilexetil: a pharmacoeconomic review of its use in chronic heart failure and hypertension

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2801628

21 June 2018

Management of patients with uncontrolled arterial hypertension--the role of electronic compliance monitoring, 24-h ambulatory blood pressure monitoring and Candesartan/HCTZ

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2801628

21 June 2018

Findings and implications of the Study on COgnition and Prognosis in the Elderly (SCOPE) - a review.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2801628

21 June 2018

Global burden of hypertension: analysis of worldwide data

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2801628

21 June 2018

Rationale and design of the avoiding cardiovascular events through combination therapy in patients living with systolic hypertension (ACCOMPLISH) trial: the first randomized controlled trial to compare the clinical outcome effects of first-line comb

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2801628

21 June 2018

Hydrochlorothiazide versus chlorthalidone: evidence supporting their interchangeability

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2801628

21 June 2018

Hypertension treatment and control in five European countries, Canada, and the United States

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2801628

21 June 2018

Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2801628

21 June 2018

Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2801628

21 June 2018

Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2801628

21 June 2018

Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2801628

21 June 2018

The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure<SUBTITLE>The JNC 7 Report</SUBTITLE>

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2801628

21 June 2018

Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2801628

21 June 2018

Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2801628

21 June 2018

Worldwide trends and shortcomings in the treatment of hypertension

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2801628

21 June 2018

Newly emerging pharmacologic differences in angiotensin II receptor blockers

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2801628

21 June 2018

The interaction of patient perception of overmedication with drug compliance and side effects

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2801628

21 June 2018

Patterns of compliance with once versus twice daily antihypertensive drug therapy in primary care: a randomized clinical trial using electronic monitoring

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2801628

21 June 2018

Effect of candesartan on microalbuminuria and albumin excretion rate in diabetes: three randomized trials.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2801628

31 October 2018

Combination therapy with candesartan cilexetil 32 mg and hydrochlorothiazide 25 mg provides the full additive antihypertensive effect of the components: A randomized, double-blind, parallel-group study in primary care

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2801628

31 October 2018

Antihypertensive efficacy and tolerability of candesartan-hydrochlorothiazide 32/12.5 mg and 32/25 mg in patients not optimally controlled with candesartan monotherapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2801628

31 October 2018

Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2801628

31 October 2018

Benefits and safety of candesartan treatment in heart failure are independent of age: insights from the Candesartan in Heart failure--Assessment of Reduction in Mortality and morbidity programme

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2801628

31 October 2018

Effect of candesartan on progression and regression of retinopathy in type 2 diabetes (DIRECT-Protect 2): a randomised placebo-controlled trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2801628

31 October 2018

Effect of candesartan on prevention (DIRECT-Prevent 1) and progression (DIRECT-Protect 1) of retinopathy in type 1 diabetes: randomised, placebo-controlled trials

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2801628

31 October 2018

Impact of diabetes on outcomes in patients with low and preserved ejection fraction heart failure: an analysis of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2801628

31 October 2018

Importance of a fixed combination of AT1-receptor blockade and hydrochlorothiazide for blood pressure lowering in cardiac risk patients. A postmarketing surveillance study with Candesartan/HCTZ

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2801628

31 October 2018

Effects of different ACE inhibitor combinations on albuminuria: results of the GUARD study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2801628

31 October 2018

Persistence with antihypertensive medication: Australia-wide experience, 2004-2006.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2801628

31 October 2018

Incident diabetes in clinical trials of antihypertensive drugs.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2801628

31 October 2018

Preventing microalbuminuria in patients with diabetes: rationale and design of the Randomised Olmesartan and Diabetes Microalbuminuria Prevention (ROADMAP) study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2801628

31 October 2018

Anti-inflammatory and metabolic effects of candesartan in hypertensive patients.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2801628

31 October 2018

Effects of candesartan on the development of a new diagnosis of diabetes mellitus in patients with heart failure

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2801628

31 October 2018

Fixed combination of candesartan with hydrochlorothiazide in patients with severe primary hypertension

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2801628

31 October 2018

Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2801628

31 October 2018

A randomized, double-blind, controlled, parallel-group comparison of perindopril and candesartan in hypertensive patients with type 2 diabetes mellitus

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2801628

31 October 2018

Metabolic outcome during 1 year in newly detected hypertensives: results of the Antihypertensive Treatment and Lipid Profile in a North of Sweden Efficacy Evaluation (ALPINE study).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2801628

31 October 2018

The ACCESS Study: evaluation of Acute Candesartan Cilexetil Therapy in Stroke Survivors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2801628

31 October 2018

The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2801628

31 October 2018

The relationships between dose and antihypertensive effect of four AT1-receptor blockers. Differences in potency and efficacy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2801628

31 October 2018

Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2801628

31 October 2018

The effect duration of candesartan cilexetil once daily, in comparison with enalapril once daily, in patients with mild to moderate hypertension

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2801628

31 October 2018

Study on COgnition and Prognosis in the Elderly (SCOPE): baseline characteristics

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2801628

31 October 2018

Pharmacokinetics of candesartan after single and repeated doses of candesartan cilexetil in young and elderly healthy volunteers.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2801628

31 October 2018

The multilevel compliance challenge: recommendations for a call to action. A statement for healthcare professionals

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2801628

31 October 2018

2007 Guidelines for the Management of Arterial Hypertension

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2801628

31 October 2018

Patterns of antihypertensive drug utilization in primary care

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2801628

31 October 2018

A comparison of the antihypertensive effects of candesartan cilexetil and losartan in patients with mild to moderate hypertension

1 reference

https://pubmed.ncbi.nlm.nih.gov/20057897

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Long-term treatment with candesartan cilexetil does not affect glucose homeostasis or serum lipid profile in mild hypertensives with type II diabetes

1 reference

https://pubmed.ncbi.nlm.nih.gov/20057897

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Thiazide-induced vasodilation in humans is mediated by potassium channel activation

1 reference

https://pubmed.ncbi.nlm.nih.gov/20057897

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Inadequate Management of Blood Pressure in a Hypertensive Population

1 reference

https://pubmed.ncbi.nlm.nih.gov/20057897

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Hemodynamic and hypotensive effects of long-term therapy with chlorothiazide

1 reference

https://pubmed.ncbi.nlm.nih.gov/20057897

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Between-country variation in the utilization of antihypertensive agents: Guidelines and clinical practice

1 reference

https://pubmed.ncbi.nlm.nih.gov/20057897

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

[Effect of candesartan cilexetil with hydrochlorothiazide on blood pressure and ST-segment depression in patients with arterial hypertension]

1 reference

https://pubmed.ncbi.nlm.nih.gov/20057897

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A comparison of the efficacy and duration of action of candesartan cilexetil and losartan as assessed by clinic and ambulatory blood pressure after a missed dose, in truly hypertensive patients: a placebo-controlled, forced titration study. Candesar

1 reference

https://pubmed.ncbi.nlm.nih.gov/20057897

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Self-reported hypertension treatment practices among primary care physicians: blood pressure thresholds, drug choices, and the role of guidelines and evidence-based medicine

1 reference

https://pubmed.ncbi.nlm.nih.gov/20057897

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Comparative pharmacodynamics and pharmacokinetics of candesartan and losartan in man

1 reference

https://pubmed.ncbi.nlm.nih.gov/20057897

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Efficacy and tolerability of a combination tablet of candesartan cilexetil and hydrochlorothiazide in insufficiently controlled primary hypertension--comparison with a combination of losartan and hydrochlorothiazide

1 reference

https://pubmed.ncbi.nlm.nih.gov/20057897

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Physician-related barriers to the effective management of uncontrolled hypertension

1 reference

https://pubmed.ncbi.nlm.nih.gov/20057897

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Hemodynamic changes during long-term thiazide treatment of essential hypertension in responders and nonresponders

1 reference

https://pubmed.ncbi.nlm.nih.gov/20057897

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The effect of prescribed daily dose frequency on patient medication compliance

1 reference

https://pubmed.ncbi.nlm.nih.gov/20057897

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.2147/VHRM.S5549

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

PMC publication ID

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33571219&oldid=1870018122"